Sandip P. Vasavada, MD

Articles by Sandip P. Vasavada, MD

Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions

ByAlon Yehoshua, PharmD, MS,Brian P. Murray, MD,Sandip P. Vasavada, MD,Peter K. Sand, MD

February 2nd 2018

This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.

Latest Updated Articles

Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions
February 2nd 2018

Sandip P. Vasavada, MD

Articles by Sandip P. Vasavada, MD

Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions

Latest Updated Articles

Trending on Pharmacy Times

Anticoagulation in AFib: Risk Stratification, Therapy Selection, and Factor XI Inhibitors

First-Ever Guideline on Cardio-Kidney-Metabolic Syndrome Calls for Earlier Screening, Coordinated Care

GLP-1 Counseling Pearls: 7 Things Every Pharmacist Should Know

Vigilance in an Age of Misinformation: Rebuilding Trust Through Evidence and Connection

Tafasitamab Regimen Improves Survival Outcomes in Newly Diagnosed High-Risk DLBCL